| Old Articles: <Older 6731-6740 Newer> |
|---|
 |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals.   |
The Motley Fool
September 29, 2010
Brian Orelli |
A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals. |
CIO
September 23, 2010
Neil Versel |
Healthcare IT: How Reform Is Giving CIOs A More Strategic Role in Delivering Patient Care Electronic health records aren't enough. Healthcare CIOs need to apply technology to coordinating patient care and measuring quality. |
The Motley Fool
September 28, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Intuitive Surgical in intensive care? Blame it on Goldman. |
The Motley Fool
September 28, 2010
Brian Orelli |
It's Up! It's Down! It's Dendreon! The joys of biotech. |
The Motley Fool
September 28, 2010
Brian Orelli |
Pfizer's Sutent Fails. Again! No surprise here. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
September 27, 2010
Brian Orelli |
Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
September 27, 2010
Brian Orelli |
Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit. |
| <Older 6731-6740 Newer> Return to current articles. |
